(Reuters) – Biogen Inc said on Thursday the U.S. Food and Drug Administration has approved changes to the product information for its Alzheimer’s disease drug to specify that it has not been studied in treating later stages of the disease.
Treatment with the drug, Aduhelm, should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, according to the updated product information on the drug.
(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)
